Brokerages Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) Target Price at $43.17

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) has been assigned a consensus recommendation of "Buy" from the eight ratings firms that are currently covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $43.17.

A number of research firms have recently issued reports on ORKA. HC Wainwright reissued a "buy" rating and set a $45.00 price target on shares of Oruka Therapeutics in a research report on Friday, December 20th. Wedbush reiterated an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a report on Tuesday, November 19th. Finally, Stifel Nicolaus initiated coverage on shares of Oruka Therapeutics in a report on Friday, October 11th. They issued a "buy" rating and a $49.00 price target for the company.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ORKA. Geode Capital Management LLC purchased a new stake in shares of Oruka Therapeutics during the third quarter worth about $343,000. The Manufacturers Life Insurance Company acquired a new stake in Oruka Therapeutics in the 3rd quarter worth approximately $1,037,000. Wellington Management Group LLP purchased a new stake in Oruka Therapeutics during the 3rd quarter worth approximately $2,013,000. Janus Henderson Group PLC acquired a new position in Oruka Therapeutics during the 3rd quarter valued at approximately $5,840,000. Finally, Redmile Group LLC purchased a new position in shares of Oruka Therapeutics in the third quarter worth $10,091,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics Stock Up 6.0 %

NASDAQ:ORKA traded up $0.73 during midday trading on Tuesday, hitting $12.98. The stock had a trading volume of 611,909 shares, compared to its average volume of 341,105. The company's 50-day simple moving average is $20.09. The stock has a market capitalization of $454.32 million, a P/E ratio of -2.07 and a beta of 0.81. Oruka Therapeutics has a one year low of $12.23 and a one year high of $53.88.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.